Domain Associates
Domain Associates is a venture capital firm with an exclusive focus on life sciences.
Business Model:
Revenue: $8.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Domain Associates Information
Geographic Data
Address: 1 Palmer Sq E
City: Princeton
State: NJ
Zip: 08542
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$164M
Social
Twitter
Linkedin
Crunchbase
Metrics
4,061,660Website Global Rank
2,913Website Monthly Traffic
Twitter Followers
Description
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Contact Phone:
+16096835656
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2007 | Evoke Pharma | Series A | 3.3M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 1/2013 | Marinus Pharmaceuticals | Series C | 21M |
| 8/2020 | Fractyl Health | Series E | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 11/2002 | Altea Therapeutics | Series B | 17M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 6/2003 | GI Dynamics | Series A | 4.1M |
| 9/2016 | Rox Medical | Series E | 40M |
| 11/2017 | Fractyl Health | Series D | 0 |
| 3/2005 | GenVault | Series A | 22.8M |
| 10/2005 | Marinus Pharmaceuticals | Series A | 29.4M |
| 2/1999 | Pointshare | Series B | 7.3M |
| 4/2003 | Ansata Therapeutics | Series B | 2.5M |
| 10/2007 | Optherion | Series A | 37M |
| 10/2000 | IntraLase | Venture Round | 22M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 4/2007 | DiObex | Series B | 24M |
| 8/1991 | Genta | Venture Round | 8.4M |
| 5/2016 | Obalon Therapeutics | Series E | 0 |
| 4/2003 | ESP Pharma | Series B | 20M |
| 12/2016 | Axial Biotherapeutics | Series A | 19.1M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
| 10/2010 | ProteinSimple | Series F | 20M |
| 12/2009 | Apnex Medical | Series B | 14M |
| 1/2007 | Esprit Pharma | Series B | 25M |
| 9/2012 | Tandem Diabetes Care | Series D | 36.4M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 7/2004 | Alimera Sciences | Series A | 26.8M |
| 4/2017 | Epic Sciences | Series D | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 10/2012 | Rightcare Solutions | Series A | 1.8M |
| 8/2022 | Fractyl Health | Series F | - |
| 2/2003 | Neose Technologies, Inc | Venture Round | 17M |
| 2/2012 | Applied Proteomics | Series B | 22.5M |
| 1/1991 | VIVUS | Seed Round | - |
| 11/2016 | Axial Biotherapeutics | Series A | 19.5M |
| 1/2017 | Adynxx | Series B | 16M |
| 7/2012 | Adynxx | Venture Round | 2M |
| 2/2011 | IntegenX | Series B | 0 |
| 4/2014 | Smart Medical Systems | Venture Round | 6.5M |
| 12/2003 | Novalar Pharmaceuticals | Series B | 5M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 10/2013 | Bionano Genomics | Series C | 0 |
| 3/2007 | Adastra Pharmaceuticals | Series A | 40M |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 3/2003 | GenVault | Series A | 10M |
| 8/2003 | GenVault | Series A | 13M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 7/2008 | Tandem Diabetes Care | Series B | 13M |
| 1/2010 | Tandem Diabetes Care | Series C | 53M |
| 12/2002 | SkinMedica | Series B | 9M |
| 7/2014 | Epic Sciences | Series C | 0 |
| 9/2015 | Kona Medical | Debt Financing | 10M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 6/2015 | Celtaxsys | Series D | 0 |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2010 | Twelve | Series A | 3M |
| 6/2012 | Twelve | Series B | 15M |
| 1/2018 | Celtaxsys | Series E | - |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 12/2012 | Kona Medical | Series C | 10M |
| 7/2008 | NovaDigm Therapeutics | Series A | 4.1M |
| 9/2005 | DiObex | Series A | 7.1M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 5/2009 | Neothetics | Series A | - |
| 2/2010 | Altair Therapeutics | Series B | 17M |
| 1/2006 | CoLucid Pharmaceuticals | Series A | 0 |
| 7/2008 | CoLucid Pharmaceuticals | Series B | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 1/2015 | CoLucid Pharmaceuticals | Series C | 0 |
| 8/2011 | CoLucid Pharmaceuticals | Venture Round | 0 |
| 8/2004 | 3F Therapeutics | Series B | 14.2M |
| 9/2004 | Vascular Architects | Series E | 0 |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 6/2003 | Eunoe | Venture Round | 40M |
| 8/2007 | Helixis | Series A | 10M |
| 11/2004 | Ascenta Therapeutics | Series B | 30M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 10/2004 | GeneOhm Sciences | Series C | 12M |
| 5/2005 | Celator Pharmaceuticals | Series B | 20M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 7/2014 | Xagenic | Series B | 0 |
| 7/2015 | Xagenic | Series B | 11.8M |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 5/2008 | Esperion | Series A | 22.8M |
| 12/2009 | Regado Biosciences | Series D | 0 |
| 3/2012 | Sequent Medical | Series C | 26M |
| 2/2008 | BioVascular | Series C | 10.9M |
| 11/2015 | Fractyl Health | Series C | 57M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 4/2011 | Ocunexus Therapeutics | Series B | 0 |
| 3/2003 | TargetRx | Series C | 0 |
| 1/2012 | Carticept Medical | Series C | 10M |
| 3/2011 | Astute Medical | Series B | 13M |
| 1/2003 | Iomai Corporation | Series C | 54M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 7/2012 | Obalon Therapeutics | Series C | 16.5M |
| 1/2004 | Orexigen Therapeutics | Series A | 11M |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 6/2008 | ROX Medical | Series C | 33M |
| 10/2013 | NovaDigm Therapeutics | Series B | 7M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 7/2020 | Nobias Therapeutics | Series A | 0 |
| 5/2020 | Seraphina Therapeutics | Series A | 0 |
| 9/2014 | Colorescience | Series B | 15M |
| 11/1999 | Medpool | Venture Round | 12M |
| 1/2014 | Atara Biotherapeutics | Series B | 13.5M |
| 6/2015 | Milestone Pharmaceuticals | Series B | 0 |
| 1/2001 | Volcano Corporation | Venture Round | - |
| 12/2007 | Corthera | Series C | 23M |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 7/2013 | aTyr Pharma | Series D | 49M |
| 7/2018 | Omniome | Series B | 0 |
| 11/2014 | Sera Prognostics | Series B | 5M |
| 5/2003 | Santarus | Series D | 51.4M |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 1/2015 | Sera Prognostics | Series B | 20M |
| 3/2007 | Regado Biosciences | Series C | 23M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 1/2010 | The Foundry | Series A | 3M |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 11/2009 | IntegenX | Series B | 18.1M |
| 6/1999 | Cardiodynamics International | Venture Round | 5M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 6/2013 | Veracyte | Series C | 28M |
| 6/2008 | Meritage Pharma | Series A | 22.5M |
| 3/2013 | Atara Biotherapeutics | Venture Round | 1M |
| 4/2010 | Achaogen | Series C | 56M |
| 7/2012 | Bionano Genomics | Series B | 0 |
| 11/2012 | Epic Sciences | Series B | 13M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 9/2010 | Eddingpharm (Cayman) | Series B | 24M |
| 5/2002 | Onyx Pharmaceuticals | Venture Round | 20M |
| 3/2000 | SelfCare.com | Venture Round | 0 |
| 9/2000 | Medpool | Venture Round | 10M |
| 9/2013 | Otonomy | Series C | 45.9M |
| 6/2016 | Miramar Labs | Venture Round | - |
| 1/2004 | Peninsula Pharmaceuticals | Series C | 0 |
| 1/2006 | ProteinSimple | Series B | 0 |
| 12/2000 | Molecular Staging | Series D | 41.3M |
| 9/2007 | Sequel Pharmaceuticals | Series A | 20M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 6/2015 | Sebacia | Series C | 12M |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 4/2007 | NovaCardia | Series B | 18M |
| 4/2014 | Sequent Medical | Series D | 20M |
| 9/2000 | Senomyx | Series B | 10M |
| 12/2011 | IntegenX | Series C | 40M |
| 3/2001 | Santarus | Series C | 33.2M |
| 12/2012 | Neothetics | Series C | 20.6M |
| 2/2014 | Neothetics | Series C | 8M |
| 8/2006 | Esprit Pharma | Series B | 90.8M |
| 1/2012 | Ariosa Diagnostics | Series C | 52.7M |
| 8/2008 | Glaukos | Series D | 35M |
| 4/2001 | iScribe | Series D | 15M |
| 9/2006 | Cantex Pharmaceuticals | Series B | 19M |
| 3/2011 | Bionano Genomics | Series B | 0 |
| 6/2003 | Orqis Medical | Series C | 25M |
| 6/2018 | WindMIL Therapeutics | Series B | 0 |
| 5/2007 | Apnex Medical | Series A | 16.1M |
| 11/2011 | Sera Prognostics | Series A | 19.3M |
| 1/2004 | Auxeris Therapeutics | Series A | 1.6M |
| 12/2001 | Aradigm | Convertible Note | 48.4M |
| 7/2012 | Ocunexus Therapeutics | Series B | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 8/2006 | Zogenix | Series A | 60M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 10/2014 | Miramar Labs | Series D | 26M |
| 12/2012 | Evofem Biosciences | Series C | 20.6M |
| 10/2013 | NovaDigm Therapeutics | Venture Round | 7M |
| 10/2006 | Ocunexus Therapeutics | Series A | 20M |
| 4/2004 | Imagine Pharmaceuticals | Series A | 3.7M |
| 4/2010 | Adastra Pharmaceuticals | Venture Round | 0 |
| 1/2008 | Zogenix | Series B | 18M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 2/2014 | Evofem Biosciences | Series C | 8M |
| 9/2012 | Rox Medical | Series D | 6M |
| 4/2005 | 3F Therapeutics | Series C | 6M |
| 10/2002 | Peninsula Pharmaceuticals | Series B | 0 |
| 8/2007 | Celator Pharmaceuticals | Series C | 10M |
| 9/2010 | Celator Pharmaceuticals | Series D | 0 |
| 10/2005 | eNeura Therapeutics | Series B | 5.1M |
| 7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
| 9/2014 | Fractyl Health | Series B | 19.8M |
| 5/1992 | NPS Pharmaceuticals | Seed Round | 5M |
| 12/1998 | OraPharma Inc. (acquired by JNJ) | Venture Round | 16M |
| 1/2009 | BiPar Sciences | Series C | 20M |
| 1/2015 | Obalon Therapeutics | Series D | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 4/2009 | ProteinSimple | Series C | 10M |
| 2/2007 | BiPar Sciences | Series B | 35M |
| 7/2003 | Corthera | Series A | 2.1M |
| 12/2005 | Celladon | Series B | 30M |
| 12/2013 | Atara Biotherapeutics | Series B | 38.5M |
| 4/2007 | Ascenta Therapeutics | Series C | 50M |
| 7/2006 | Ocera Therapeutics | Series B | 12M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 5/2009 | Marinus Pharmaceuticals | Series B | 20M |
| 10/2012 | Veracyte | Private Equity Round | 14.9M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 5/2004 | NuVasive | Venture Round | 9.8M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 6/2008 | GenVault | Series B | 13M |
| 4/2013 | Esperion | Venture Round | 33M |
| 5/2007 | Asmacure Ltée | Series A | 9M |
| 8/2013 | Applied Proteomics | Series C | 28M |
| 4/2017 | ChromaCode | Series B | 12M |
| 4/2005 | TargetRx | Series D | 0 |
| 12/2019 | ChromaCode | Series C | 0 |
| 1/2005 | NeuroPace | Venture Round | 30M |
| 1/2020 | Omniome | Series C | 60M |
| 4/2001 | Xcel Pharmaceuticals | Venture Round | 70M |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 4/2013 | Afferent Pharmaceuticals | Series B | 5M |
| 7/2009 | Oraya Therapeutics | Series C | 42M |
| 9/1993 | GelTex Pharmaceuticals | Venture Round | 6.8M |
| 12/2012 | Regado Biosciences | Series E | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 5/2012 | Kona Medical | Series C | 0 |
| 4/2005 | Orexigen Therapeutics | Series B | 35M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 12/2001 | Pharmion | Venture Round | 65M |
| 11/2018 | Antios Therapeutics | Series A | 0 |
| 7/2010 | ReVision Optics | Series D | 35M |
| 6/2000 | TargetRx | Series B | 12M |
| 8/2010 | Otonomy | Series B | 38.5M |
| 4/2007 | GenVault | Venture Round | 18M |
| 1/2005 | GeneOhm Sciences | Series C | 0 |
| 6/2000 | Align Technology | Series D | 105M |
| 4/2005 | Receptor Biologix | Series A | 33.6M |
| 10/2010 | aTyr Pharma | Series C | 23M |
| 2/2012 | Apnex Medical | Series C | 20M |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 9/2005 | Esprit Pharma | Series A | 103.7M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 5/2004 | GI Dynamics | Series B | 0 |
| 10/2009 | Alimera Sciences | Series C | 5M |
| 6/2010 | Corridor Pharmaceuticals | Series A | 0 |
| 2/2019 | Axial Biotherapeutics | Series B | 25M |
| 4/2014 | Otonomy | Series D | 49M |
| 3/2000 | iScribe | Series B | 21M |
| 4/2005 | SkinMedica | Series E | 0 |
| 4/2006 | SkinMedica | Series E | 0 |
| 9/2014 | Zyga Technology | Series D | 2M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2004 | Novacea | Series C | 35M |
| 11/2002 | Novacea | Series B | 36M |
| 4/2015 | Twelve | Series C | 35M |
| 2/2011 | Glaukos | Series E | 0 |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 8/2002 | Proxima Therapeutics | Series E | 14M |
| 2/2001 | Proxima Therapeutics | Series D | 17M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 11/2005 | Alimera Sciences | Series B | 31.8M |
| 6/2004 | Somaxon Pharmaceuticals | Series B | 23M |
| 10/2009 | Zogenix | Series B | 36M |
| 3/2008 | Alimera Sciences | Series C | 30M |
| 7/2004 | SkinMedica | Series D | 30M |
| 12/2001 | TargetRx | Series C | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 1/2008 | Sonexa Therapeutics | Series A | 0 |
| 11/2019 | Truvian Sciences | Series B | 27.1M |
| 11/2004 | Corthera | Series B | 15M |
| 5/2000 | Beansprout.net | Series C | 21.3M |
| 10/1999 | Align Technology | Venture Round | 0 |
| 6/2010 | Veracyte | Series B | 28M |
| 7/2020 | Exalys Therapeutics | Series A | 15M |
| 7/2005 | Immune Control | Series A | 0 |
| 12/2007 | REVA Medical | Venture Round | 42M |
| 2/2008 | Obalon Therapeutics | Series A | 4.7M |
| 11/2016 | Gene Sciences, Inc. | Series A | 8M |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 3/2010 | Carticept Medical | Series B | 20M |
| 2/2007 | Carticept Medical | Series A | - |
| 3/2007 | Orqis Medical | Series D | 12M |
| 4/2007 | ReVision Optics | Series D | 25M |
| 12/1987 | Viagene | Seed Round | 1M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 1/2016 | Singular Genomics | Seed Round | - |
| 4/2005 | NovaCardia | Series A | - |
| 9/2006 | NovaCardia | Series B | 48M |
| 10/2012 | Cotera | Venture Round | 5M |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 9/2002 | Glaukos | Series A | 10M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 11/2013 | Rightcare Solutions | Series B | 5M |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 8/2020 | Fractyl Health | Series E | 0 |
| 7/2020 | Nobias Therapeutics | Series A | 0 |
| 7/2020 | Exalys Therapeutics | Series A | 0 |
| 5/2020 | Seraphina Therapeutics | Series A | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 1/2020 | Omniome | Series C | 0 |
| 12/2019 | ChromaCode | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
